Table 2.

TEAEs occurring in ≥20% of patients (part A)

TEAE	1 g QD (n = 3), n (%)	2 g QD (n = 7), n (%)	5 g QD (n = 8), n (%)	10 g QD (n = 4), n (%)	15 g QD (n = 3), n (%)	2 g BID (n = 3), n (%)	5 g BID (n = 4), n (%)	Total (n = 32), n (%)
Any event	3 (100)	7 (100)	8 (100)	4 (100)	3 (100)	3 (100)	4 (100)	32 (100)
Diarrhea	0	3 (43)	3 (38)	4 (100)	3 (100)	1 (33)	1 (25)	15 (47)
Fatigue	0	4 (57)	2 (25)	1 (25)	3 (100)	2 (67)	3 (75)	15 (47)
Nausea	1 (33)	4 (57)	4 (50)	1 (25)	2 (67)	2 (67)	1 (25)	15 (47)
Vomiting	0	3 (43)	3 (38)	3 (75)	2 (67)	1 (33)	2 (50)	14 (44)
Dyspnea	1 (33)	4 (57)	4 (50)	1 (25)	1 (33)	1 (33)	1 (25)	13 (41)
Decreased appetite	0	3 (43)	2 (25)	1 (25)	2 (67)	1 (33)	2 (50)	11 (34)
Cough	1 (33)	2 (29)	3 (38)	1 (25)	0	0	1 (25)	8 (25)
Hypernatremia	0	2 (29)	2 (25)	2 (50)	0	1 (33)	1 (25)	8 (25)
Pyrexia	0	2 (29)	3 (38)	0	1 (33)	0	2 (50)	8 (25)
Constipation	0	2 (29)	2 (25)	0	1 (33)	1 (33)	1 (25)	7 (22)

BID, twice‐daily; QD, once daily; TEAE, treatment‐emergent adverse event.